Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

754 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evaluation of triple negative breast cancer with heterogeneous immune infiltration.
Quintana Á, Arenas EJ, Bernadó C, Navarro JF, González J, Esteve-Codina A, Moliné T, Marti M, Curigliano G, Schmid P, Peg V, Arribas J, Cortés J. Quintana Á, et al. Among authors: curigliano g. Front Immunol. 2023 May 4;14:1149747. doi: 10.3389/fimmu.2023.1149747. eCollection 2023. Front Immunol. 2023. PMID: 37215143 Free PMC article.
How I treat endocrine-dependent metastatic breast cancer.
Gombos A, Goncalves A, Curigliano G, Bartsch R, Kyte JA, Ignatiadis M, Awada A. Gombos A, et al. Among authors: curigliano g. ESMO Open. 2023 Apr;8(2):100882. doi: 10.1016/j.esmoop.2023.100882. Epub 2023 Feb 17. ESMO Open. 2023. PMID: 36806375 Free PMC article. Review.
PD-L1 testing in metastatic triple-negative breast cancer: Interobserver and interplatform reproducibility of CE-IVD assays for CPS and IC scores.
Ivanova M, Frascarelli C, Cerbelli B, Pignataro MG, Pernazza A, Venetis K, Sajjadi E, Criscitiello C, Curigliano G, Guerini-Rocco E, Graziano P, Martini M, d'Amati G, Fusco N. Ivanova M, et al. Among authors: curigliano g. Hum Pathol. 2024 Feb;144:22-27. doi: 10.1016/j.humpath.2024.01.008. Epub 2024 Jan 24. Hum Pathol. 2024. PMID: 38278450
Antibody-Drug Conjugates in Breast Cancer: What Is Beyond HER2?
Nicolò E, Repetto M, Boscolo Bielo L, Tarantino P, Curigliano G. Nicolò E, et al. Among authors: curigliano g. Cancer J. 2022 Nov-Dec 01;28(6):436-445. doi: 10.1097/PPO.0000000000000629. Cancer J. 2022. PMID: 36383906 Review.
Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021.
Burstein HJ, Curigliano G, Thürlimann B, Weber WP, Poortmans P, Regan MM, Senn HJ, Winer EP, Gnant M; Panelists of the St Gallen Consensus Conference. Burstein HJ, et al. Among authors: curigliano g. Ann Oncol. 2021 Oct;32(10):1216-1235. doi: 10.1016/j.annonc.2021.06.023. Epub 2021 Jul 6. Ann Oncol. 2021. PMID: 34242744 Free PMC article. Review.
News from the San Antonio Breast Cancer Symposium 2022.
Gennari A, Curigliano G, Del Mastro L, Guarneri V, Puglisi F, Zambelli A. Gennari A, et al. Among authors: curigliano g. Breast Care (Basel). 2023 Jun;18(3):223-227. doi: 10.1159/000530183. Epub 2023 Mar 16. Breast Care (Basel). 2023. PMID: 37928813 No abstract available.
Think "HER2" different: integrative diagnostic approaches for HER2-low breast cancer.
Marchiò C, Criscitiello C, Scatena C, Santinelli A, Graziano P, Malapelle U, Cursano G, Venetis K, Fanelli GN, Pepe F, Berrino E, Angelis C, Perrone G, Curigliano G, Fusco N. Marchiò C, et al. Among authors: curigliano g. Pathologica. 2023 Dec;115(6):292-301. doi: 10.32074/1591-951X-942. Pathologica. 2023. PMID: 38180137 Free PMC article. Review.
Clinical actionability of BRCA2 alterations in uterine leiomyosarcoma: a molecular tumor board case report and a cBioPortal comprehensive analysis.
Boscolo Bielo L, Repetto M, Crimini E, Belli C, Setola E, Parma G, Fusco N, Barberis M, Guerini Rocco E, Marra A, Colombo N, Curigliano G. Boscolo Bielo L, et al. Among authors: curigliano g. Oncologist. 2024 May 8:oyae082. doi: 10.1093/oncolo/oyae082. Online ahead of print. Oncologist. 2024. PMID: 38716772 Free article.
Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study.
Li BT, Meric-Bernstam F, Bardia A, Naito Y, Siena S, Aftimos P, Anderson I, Curigliano G, de Miguel M, Kalra M, Oh DY, Park JO, Postel-Vinay S, Rha SY, Satoh T, Spanggaard I, Michelini F, Smith A, Machado KK, Saura C; DESTINY-PanTumor01 study group. Li BT, et al. Among authors: curigliano g. Lancet Oncol. 2024 May 3:S1470-2045(24)00140-2. doi: 10.1016/S1470-2045(24)00140-2. Online ahead of print. Lancet Oncol. 2024. PMID: 38710187
754 results